A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer

A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer - A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027632

Enrollment

Registered

2017-07-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

1, Administration of immune-enhancing enteral nutrients from 2 weeks before surgery to 3 weeks after surgery. The dose of nutrients depends on the phase from 480kcal to 960kcal, 2. Administration of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with pancreatic cancer 2. Patients who will undergo Pancreaticoduodenectomy 3. ECOG-PS 0 or 1 4. Patients who can intake orally 5. Patients who fully understand the study procedures and consent the document voluntary after an adequate explanation

Exclusion criteria

Exclusion criteria: 1. Patients with active double cancer 2. Patients who have active infection 3. Patients who need to restrict food or water intake 4. Patients with milk or soy allergy 5. Patients with pancrelipase allergy 6. Patients with pork protein allergy 7. Patients with ileus 8. Patients with advanced liver dysfunction or advanced renal dysfunction 9. Patients with abnormal glucose metabolism, such as severe diabetes 10. Patients with congenital disorders of amino acid metabolism 11. Patients with pregnancy 12. Patients who were deemed inappropriate for medical reasons

Design outcomes

Primary

Measure	Time frame
Treatment completion rate of preoperative ingestion of immunoenhancing enteral nutrients and pancrelipase	—

Countries

Japan

Contacts

Public ContactSuguru Yamada

Nagoya University, Graduate School of Medicine Gastroenterorogical Surgery

suguru@med.nagoya-u.ac.jp052-744-2253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026